−Removed: investment in our common stock involves a number of very significant risks.
−Removed: You should carefully consider the risk factor set forth below,
−Removed: the risk factors included in the “Risk Factors” section of Amendment No.
−Removed: 1 to our Annual Report on Form 10-K/A for the year
−Removed: ended December 31, 2023, as filed with the SEC on June 11, 2024, and the other information contained in that report and in this quarterly
−Removed: report in evaluating the Company and its business before purchasing shares of our common stock.
−Removed: The Company’s business, operating
−Removed: results and financial condition could be adversely affected due to any of those risks.
−Removed: Related to Our Cell Therapy Product Development Efforts
−Removed: activity as a contract manufacturer of biologic-based cosmetics could result in FDA enforcement for reasons outside of our control, which
−Removed: could disrupt the development of our own product candidates or harm our reputation.
−Removed: manufacture a commercial product as a contract manufacturer for a third-party company, Cartessa Aesthetics, LLC (“Cartessa”).
−Removed: While we believe the product we manufacture for Cartessa is intended for cosmetic uses, we (as the contract manufacturer) do not ultimately
−Removed: have control over how the product is marketed.
−Removed: It is possible that the FDA could determine, based on how the product is marketed (among
−Removed: other considerations), that it is intended for unapproved therapeutic use(s), which could result in the temporary or permanent suspension
−Removed: of manufacturing and/or commercialization of the product and/or a wide range of enforcement actions, such as warning letters, recall,
−Removed: ‘dear doctor’ letters, and others.
−Removed: If the FDA takes enforcement action against Cartessa or us in connection with this product,
−Removed: it could have an adverse impact on our operations and/or harm our reputation as a biologics company.
+Added: An investment in our common stock
+Added: involves a number of very significant risks.
+Added: You should carefully consider the risk factors included in the “Risk Factors”
+Added: section of our Annual Report on Form 10-K for the year ended December 31, 2024, as filed with the SEC on March 28, 2025, and the other
+Added: information contained in that report and in this quarterly report in evaluating the Company and its business before purchasing shares
+Added: of our common stock.
+Added: Our business, operating results and financial condition could be adversely affected due to any of those risks.
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.